Core Insights - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders related to neuronal excitation-inhibition imbalance [1][3] - The company will participate in three upcoming investor conferences, providing opportunities for one-on-one meetings with interested investors [1][4] Company Overview - Praxis utilizes genetic insights from epilepsy to develop therapies for CNS disorders through its proprietary platforms, Cerebrum™ and Solidus™ [3] - The company has a diversified portfolio that includes multiple programs targeting epilepsy and movement disorders, with four clinical-stage product candidates [3] Upcoming Events - Praxis will present at the Baird 2025 Global Healthcare Conference on September 9th from 9:00-9:35am EDT [4] - A fireside chat is scheduled for September 10th at the H.C. Wainwright 27th Annual Global Investment Conference at 8:30am EDT [4] - A virtual corporate presentation will take place on September 18th at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit from 3:00-3:30pm EDT [4]

Core Insights - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders through genetic insights [1][2] - The company will have its CEO Marcio Souza participate in a virtual fireside chat hosted by Truist Securities on August 5, 2025 [1] Company Overview - Praxis specializes in translating insights from genetic epilepsies into therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance [2] - The company utilizes its proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, to develop therapies for both rare and prevalent neurological disorders [2] - Praxis has a diversified CNS portfolio that includes multiple programs across epilepsy and movement disorders, featuring four clinical-stage product candidates [2]

BOSTON, July 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report topline results from the RADIANT trial of vormatrigine and its financial results from the second quarter ended June 30, 2025, before the financial markets open on Monday, August 4, 2 ...

Company Overview - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance [3] - The company utilizes genetic insights to create therapies for both rare and prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [3] - Praxis has a diversified CNS portfolio that includes multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates [3] Upcoming Events - The company will participate in three investor conferences, including a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20 at 9:30 am ET [4] - Praxis management will also attend the Mizuho Neuro & Ophthalmology Summit in New York City on May 21 [4] - A corporate overview will be presented at the Jefferies Global Healthcare Conference on June 4 at 8:10 am ET [4] Investor Engagement - The company will be available for one-on-one meetings during all events, encouraging interested investors to contact their representatives [1] - Webcasts of the events will be accessible for 90 days through the "Events & Presentations" page on the company's website [2]